Want to see AU:CMP full AI Analyst Report?
CMP Stock Chart & Stats
AU$0.34
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.34
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.23 - AU$0.45
Previous CloseN/A
Volume3.00K
Average Volume (3M)87.45K
Market Cap
AU$50.94M
Enterprise ValueAU$64.97M
Total Cash (Recent Filing)AU$2.00M
Total Debt (Recent Filing)AU$14.03M
Price to Earnings (P/E)637.5
Beta0.66
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding199,761,750
10 Day Avg. Volume153,799
30 Day Avg. Volume87,448
Financial Highlights & Ratios
PEG Ratio-0.14
Price to Book (P/B)2.12
Price to Sales (P/S)0.91
P/FCF Ratio99.22
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.04
Revenue Forecast (FY)AU$80.10M
Bulls Say, Bears Say
Bulls Say
High Gross MarginsA 60.71% gross margin indicates strong product-level economics driven by specialized diagnostic hardware and software. These margins provide a durable buffer to fund R&D, service networks and pricing flexibility, improving the outlook for sustainable profitability as volumes scale.
Diversified, Recurring Revenue MixCompumedics’ mix of capital equipment, software licenses, consumables and service contracts creates multiple recurring revenue streams. Installed-base aftermarket sales and service contracts support revenue durability and higher lifetime customer value versus pure-capex businesses.
Manageable LeverageA debt-to-equity ratio around 0.64 signals moderate leverage and preserved financial flexibility. This capital structure reduces immediate refinancing risk, enabling targeted investment in product development, service capacity and working capital without excessive strain during normal industry cycles.
Bears Say
Weak ProfitabilityNegative net margin and minimal EBIT margin show the company struggles to convert sales into sustainable profits despite healthy gross margins. Persistent weak returns (negative ROE) limit internal funding for growth, reduce resilience to cost shocks, and hinder long-term value creation.
Poor Cash GenerationSeverely negative free cash flow growth and very low operating cash-to-income indicate weak cash conversion. Limited cash generation constrains R&D and service investments, increases reliance on external financing, and raises vulnerability to working-capital swings or unexpected expenditures.
Cyclicality Of DemandRevenue depends on hospital and clinic capital budgets and replacement cycles, creating structural demand volatility and long sales cycles. This makes forecasting and resource allocation harder, and can produce uneven revenue and cash flow over multi-quarter horizons.
Compumedics Limited News
CMP FAQ
What was Compumedics Limited’s price range in the past 12 months?
Compumedics Limited lowest share price was AU$0.23 and its highest was AU$0.45 in the past 12 months.
What is Compumedics Limited’s market cap?
Compumedics Limited’s market cap is AU$50.94M.
When is Compumedics Limited’s upcoming earnings report date?
Compumedics Limited’s upcoming earnings report date is Aug 27, 2026 which is in 57 days.
How were Compumedics Limited’s earnings last quarter?
Compumedics Limited released its earnings results on Feb 24, 2026. The company reported AU$0.001 earnings per share for the quarter, beating the consensus estimate of N/A by AU$0.001.
Is Compumedics Limited overvalued?
According to Wall Street analysts Compumedics Limited’s price is currently Overvalued.
Does Compumedics Limited pay dividends?
Compumedics Limited does not currently pay dividends.
What is Compumedics Limited’s EPS estimate?
Compumedics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Compumedics Limited have?
Compumedics Limited has 199,761,750 shares outstanding.
What happened to Compumedics Limited’s price movement after its last earnings report?
Compumedics Limited reported an EPS of AU$0.001 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.353%.
Which hedge fund is a major shareholder of Compumedics Limited?
Currently, no hedge funds are holding shares in AU:CMP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Compumedics Limited Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
13.56%
12-Months-Change
Fundamentals
Return on Equity
0.48%
Trailing 12-Months
Asset Growth
13.30%
Trailing 12-Months
Company Description
Compumedics Limited
Compumedics Limited is a global medical technology enterprise engaged in the full lifecycle of designing, producing, marketing, and distributing advanced diagnostic medical devices. Its market reach extends across Australia, the Asia Pacific region, the Americas, Europe, and the Middle East. The company's product portfolio is primarily focused on solutions for sleep and neurological disorders. For sleep diagnostics, offerings include sophisticated PSG:EEG amplification systems like the Grael 4K, portable recording units such as the Somté PSG and Siesta 802, wearable monitoring devices like Somfit/Somfit Pro, and transcutaneous monitors (e.g., TCM5 FLEX). In the field of neurology, Compumedics supplies devices like the ONsight A.V.S. for home ambulatory studies, a variety of EEG amplifiers (e.g., Grael 4K-EEG, Grael LT EEG), comprehensive long-term EEG monitoring systems (Neuvo 64-512 Channel LTM), and specialized EMG/EP systems (including Xegis Forte and Xegis G:NEO). Complementing its hardware, the company develops an extensive range of software, featuring the Profusion Sleep and EEG platforms, Profusion neXus 360 (a web-based system for patient data and lab management), a Multi-Modal Neuroimaging Suite, and workflow optimization tools like Profusion neXus Laboratory Management and Scheduler. Other software offerings include HD Digital Video integration and various specialized applications. Furthermore, Compumedics provides magnetoencephalography systems, cutting-edge brain research technologies, services for pharmaceutical clinical trials and research, as well as a diverse array of accessories and consumables crucial for diagnostic and research endeavors. Established in 1987, Compumedics Limited is based in Abbotsford, Australia, and functions as a subsidiary of D & DJ Burton Holdings Pty Ltd.
Technical Analysis
Impedimed Limited
―
Somnomed Limited
―
Cyclopharm Limited
―
EMvision Medical Devices Ltd.
―
Control Bionics Ltd.
―